Company overview
IDBS offers comprehensive laboratory informatics solutions, including LIMS, ELNs, LES, and data integration tools, tailored for life sciences and pharmaceutical R&D through manufacturing. These platforms streamline workflows, enhance data management, ensure GxP compliance, and support BioPharma organizations, CROs, and sponsors in accelerating time-to-market. With over 35 years of experience, IDBS delivers cloud-based and enterprise systems like Polar and E-WorkBook for unified data capture and AI-driven insights.
IDBS is listed in the NovaPharmaNews Supplier Hub as a Software & Digital Lab partner serving United States & Americas. Core focus areas include idbs, laboratory informatics, lims, eln, gxp compliant.
Industry categories: Software & Digital Lab. These tags help R&D, manufacturing, and procurement teams discover vendors aligned with their pipeline stage and compliance requirements.
Structured facts
- Website
- https://www.idbs.com/
- Categories
- Software & Digital Lab
- Markets served
- United States & Americas
- Keywords
- idbs, laboratory informatics, lims, eln, gxp compliant
Products & technologies
Markets served
Industry categories
Company timeline
- — Profile published on NovaPharmaNews
- — Profile last updated
Related suppliers in category
Frequently asked questions
- What core capabilities does IDBS provide for pharma labs?
- IDBS provides LIMS for sample and workflow management, ELNs for electronic documentation, LES for SOP execution and compliance, and data integration tools for analytics and insights across R&D and manufacturing.
- Is IDBS compliant with GxP regulations?
- Yes, IDBS Polar is GxP-compliant for enterprise lab informatics in both GxP and non-GxP environments, ensuring data integrity, quality control, and regulatory adherence.
- What geographies and support does IDBS offer?
- IDBS delivers global support teams with over 35 years of experience, serving world-leading BioPharma organizations, CROs, and sponsors worldwide through cloud-based platforms like E-WorkBook.
Related editorial coverage
- Teva Reports Strong Q1 2026 Results as PONLIMSI Biosimilar Receives FDA Approval and Olanzapine LAI Advances
- Teva's PONLIMSI Biosimilar Receives FDA Approval for All Prolia Indications as Q1 2026 Results Show Strong Growth
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
Explore lab tools and QA/QC resources for R&D teams.
